Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: trouble (31), riot (2), disorder (273)

Commercial filming protocol

Description: Commercial and production filming policy 1 Introduction University Hospital Southampton NHS Foundation Trust is a po
Url: /Media/UHS-website-2019/Docs/Policies/Commercial-filming-protocol.pdf

HSCT Amb Melphalan-Bortezomib SC

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT AUTOGRAFT AMBULATORY MELPHALAN and BORTEZOMIB SC Multiple Myeloma This regimen will only be available to prescribe at units which carry out
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCT-Amb-Melphalan-Bortezomib-SC-Ver1.pdf

Nivolumab-Relatlimab

Description: Chemotherapy Protocol SKIN CANCER Nivolumab in combination with Relatlimab (Opdualag) Regimen • Skin – Nivolumab in in combination with Relatlimab (Opdualag) Indication The
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-Relatlimab-Ver1.pdf

Talimogene laherparepvec (T-VEC)

Description: Chemotherapy Protocol SKIN CANCER Talimogene laherparepvec (T-VEC) Regimen • Skin – Talimogene laherparepvec (T-VEC) Indication • Talimogene laherparepvec (T-VEC) is recommended
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Talimogene-laherparepvec-T-VEC.pdf

Cyclophosphamide-Epirubicin-Paclitaxel 21day

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel Indication • Neoadjuvant / adjuvant therapy of early breast cancer
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Cyclophosphamide-Epirubicin-Paclitaxel-21day.pdf

Huntington disease (HD) - patient information

Description: This booklet is for people who have a family history of Huntington disease (HD) and would like to understand more about
Url: /Media/UHS-website-2019/Patientinformation/Genetics/Huntington-disease-HD-1437-PIL.pdf

Bevacizumab(15mgkg) Carboplatin Gemcitabine (day1)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (15)-CARBOPLATIN (AUC4)-GEMCITABINE (day 1) This protocol may require funding Regimen • Ovary-Bevacizumab (15)-Carboplatin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Bevacizumab15mgkg-Carboplatin-Gemcitabine-day1.pdf

Carboplatin (AUC4.5) Gemcitabine

Description: Chemotherapy Protocol BLADDER CARBOPLATIN (AUC4.5)-GEMCITABINE Regimen  Bladder-Carboplatin-Gemcitabine Indication  Locally advanced or metastatic urothelial cancer  WHO performance status
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Carboplatin-AUC4.5-Gemcitabine.pdf

Carboplatin (AUC6) Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN Retreat Regimen (AUC6) • Ovary – Carboplatin (AUC6) Retreat Indication • Second line or subsequent treatment of platinum sensitive
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC6Retreat.pdf

Carboplatin (AUC5) Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN Retreat (AUC5) Regimen • Ovary – Carboplatin (AUC5) Retreat Indication • Second line or subsequent treatment of platinum sensitive
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC5-Retreat.pdf

131 to 140 of 282

Previous … 12 13 14 15 16 … Next